INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34901, 1947, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34902, 3939, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34903, 4042, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34904, 8090, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34905, 10403, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34906, 11625, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34907, 13595, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34908, 13710, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34909, 15419, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34910, 15682, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34911, 15725, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34912, 15726, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34913, 21356, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34914, 21365, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34915, 21833, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34916, 22182, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34917, 24198, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34918, 25869, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34919, 26187, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34920, 27022, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34921, 30248, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34922, 1872, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34923, 1876, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34924, 1879, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34925, 1906, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34926, 1947, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34927, 3939, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34928, 4042, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34929, 8090, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34930, 10403, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34931, 11625, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34932, 13595, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34933, 13710, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34934, 15419, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34935, 15682, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34936, 15725, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34937, 15726, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34938, 21356, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34939, 21365, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34940, 21833, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34941, 22182, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34942, 24198, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34943, 25869, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34944, 26187, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34945, 27022, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34946, 30248, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34947, 1872, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34948, 1876, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34949, 1879, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34950, 1906, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34951, 1947, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34952, 3939, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34953, 4042, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34954, 8090, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34955, 10403, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34956, 11625, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34957, 13595, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34958, 13710, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34959, 15419, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34960, 15682, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34961, 15725, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34962, 15726, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34963, 21356, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34964, 21365, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34965, 21833, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34966, 22182, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34967, 24198, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34968, 25869, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34969, 26187, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34970, 27022, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34971, 30248, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34972, 202, 'Calcium gluconate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34973, 202, 'Calcium gluconate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34974, 202, 'Calcium gluconate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34975, 202, 'Calcium gluconate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34976, 202, 'Calcium gluconate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34977, 17544, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34978, 17545, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34979, 20920, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34980, 20921, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34981, 24578, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34982, 24579, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34983, 17544, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34984, 17545, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34985, 20920, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34986, 20921, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34987, 24578, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34988, 24579, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34989, 17544, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34990, 17545, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34991, 20920, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34992, 20921, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34993, 24578, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34994, 24579, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34995, 17544, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34996, 17545, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34997, 20920, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34998, 20921, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34999, 24578, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (35000, 24579, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '', 'DDInter', 0);
